Why is Insmed stock surging today?

Insmed stock surged 14.5% in pre-open trading after the biopharmaceutical company reported third-quarter 2026 revenues of $524.4 million, comfortably topping the consensus estimate of roughly $497–$499 million and representing a dramatic year-over-year increase from the $142.3 million reported in Q3 2025. The standout performer was BRINSUPRI (brensocatib), which generated $400.1 million in quarterly revenue — a 29% jump from the prior quarter — confirming the rapid commercial ramp of the company’s flagship bronchiectasis therapy.

Beyond the top-line beat, management raised full-year 2026 revenue guidance for BRINSUPRI to $1.35–$1.40 billion, up from the prior range of $1.25–$1.40 billion, and lifted the ARIKAYCE outlook to $460–$470 million from $450–$470 million. The company also indicated it remains on track to achieve cash flow positivity in 2027, a milestone investors have been closely watching. These upward revisions provided an additional confidence boost that amplified the initial earnings reaction. On the downside, Q3 EPS came in at -$0.46, missing the consensus estimate of around -$0.39, though the market appeared to look past the bottom-line shortfall given the strength of the commercial execution.

The broader market offered little tailwind today, with the S&P 500 slipping 0.3%, the Dow Jones easing 0.2%, and the Nasdaq declining 1.1%, making INSM’s pre-market move a clearly company-driven event rather than a sector-wide lift. The stock had been under pressure in recent weeks — trading near its 52-week low of $90.39 — after a CFO transition announcement weighed on sentiment, so the earnings beat arrived at a technically sensitive moment for the shares.

Taken together, the combination of a meaningful revenue beat, raised guidance on both key products, and a credible path to profitability proved sufficient to overcome both the EPS miss and a weak macro backdrop, sending INSM sharply higher to trade at $111 in pre-market — still well below its 52-week high of $212.75 but a significant recovery from recent lows.